Comorbidities in prurigo nodularis.

Area of Science:

• Dermatology
• Immunology
• Neurology

Background:

• Prurigo nodularis (PN) is a chronic inflammatory skin disease defined by severe itch and hyperkeratotic nodules.
• Its pathogenesis involves complex neuroimmune dysregulation with inflammatory cytokines and neuropeptides.
• PN substantially diminishes patients' quality of life, more so than other chronic pruritic conditions.

Purpose of the Study:

• To summarize the current understanding of Prurigo nodularis pathogenesis, clinical presentation, and management.
• To highlight the significant impact of PN on patient quality of life.
• To underscore the importance of identifying and managing comorbidities associated with PN.

Main Methods:

• Review of existing literature on Prurigo nodularis.
• Analysis of the role of neuroimmune pathways in PN.
• Evaluation of systemic and psychiatric comorbidities linked to PN.
• Assessment of current and emerging treatment strategies.

Main Results:

• PN pathogenesis involves neuroimmune dysregulation and inflammatory mediators.
• Patients with PN experience greater disease severity, itch intensity, and reduced quality of life.
• PN is linked to numerous systemic comorbidities (e.g., CKD, cardiovascular disease, HIV) and psychiatric conditions (e.g., depression, anxiety).
• Neurologic comorbidities like neuropathic pain and sleep disturbances are also prevalent.

Conclusions:

• Comprehensive assessment for comorbidities is crucial for personalized PN management.
• Treatment aims to alleviate itch and improve quality of life, utilizing immunosuppressants, neuromodulators, or biologics like dupilumab.
• Further research into PN pathogenesis and targeted therapies is warranted.